Patients with tumor grade 3 (OR = 7.64, p = 0.008), higher PR positive receptor status (OR = 2.85, p = 0.04), and invasive lobular histology (OR = 4.52, p = 0.02) were more likely to be predicted to benefit from EET compared with those with ductal histology. The gene discussed is PGR; the disease is neoplasm.